TRANSPLANT-INELIGIBLE 2ND LINE DLBCL

Clinical trials for TRANSPLANT-INELIGIBLE 2ND LINE DLBCL explained in plain language.

Never miss a new study

Get alerted when new TRANSPLANT-INELIGIBLE 2ND LINE DLBCL trials appear

Sign up with your email to follow new studies for TRANSPLANT-INELIGIBLE 2ND LINE DLBCL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Engineered immune cells take on tough lymphomas

Disease control Recruiting now

This phase 2 trial tests a personalized cell therapy called zamtocabtagene autoleucel (MB-CART2019.1) for people with B cell lymphomas that have come back or not responded to standard treatments. Participants receive their own immune cells that have been genetically modified to r…

Matched conditions: TRANSPLANT-INELIGIBLE 2ND LINE DLBCL

Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control

Last updated Jul 15, 2026 00:00 UTC

TRANSPLANT-INELIGIBLE 2ND LINE DLBCL

Get alerted when new TRANSPLANT-INELIGIBLE 2ND LINE DLBCL trials appear

Engineered immune cells take on tough lymphomas